# Lipid Synthesis: Building Cholesterol from Acetyl-CoA

> Cells get cholesterol two ways, by building it from two-carbon acetyl-CoA and by taking up LDL through the LDL receptor, and one gauge, the cholesterol level in the ER membrane read by SCAP, sets both through SREBP-2. Statins block HMG-CoA reductase, the main throttle; the gauge reads low, the liver makes more LDL receptors, and LDL leaves the blood. The same gauge explains familial hypercholesterolemia and why PCSK9 inhibitors add to a statin.

Course: Biochemistry (Fuels, Fat & Nitrogen). Level: university elective. About 25 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/lipid-synthesis/

Builds on: Metabolism: Basic Concepts and Design · Membranes: The Impermeable Sheet That Builds Itself · Fatty Acid Synthesis: Building the Chain Two Carbons at a Time

## What you'll learn

- Trace cholesterol biosynthesis through its three stages — condense (acetyl-CoA to mevalonate), assemble (C5 isoprenoid units to C30 squalene), and cyclize (squalene to lanosterol to cholesterol) — and account for the carbons (36 brought in by 18 acetyl-CoA, 30 in squalene, 27 in cholesterol) and the cost (18 ATP, 14 NADPH to 2,3-oxidosqualene).
- Explain why the main throttle sits at HMG-CoA reductase, the rate-limiting, irreversible step that commits carbon to the shared mevalonate trunk, and why blocking it lowers CoQ10 and the prenyl anchors while blocking squalene synthase does not.
- Describe receptor-mediated endocytosis of LDL via ApoB-100 and the LDL receptor, explain why familial hypercholesterolemia is a disorder of uptake rather than synthesis, and account for how PCSK9 and its inhibitors reset serum LDL.
- Explain how one ER sterol gauge (SCAP senses, Insig binds SCAP, SREBP-2 is the passenger) runs both synthesis and LDL-receptor production, place the four controls on HMG-CoA reductase (transcription via SREBP, mRNA/translation, AMPK phosphorylation at Ser872, and sterol-triggered degradation) by what each reads, and explain how statins lower serum LDL by a double mechanism.
- Name what cholesterol becomes — membranes first, then bile salts, glucocorticoids/mineralocorticoids/sex steroids, and vitamin D — and connect specific tissue enzymes (the P450s aromatase and CYP7A1, and 5alpha-reductase) to named drugs.
- Going deeper: diagram the phosphatidate hub, how glycerol-3-phosphate is doubly acylated to phosphatidate, and how PAP/Lipin 1 localization tilts the carbon toward storage triacylglycerol or toward membrane phospholipids made through CDP-DAG.

**The film above opens with Brown and Goldstein’s familial hypercholesterolemia (FH) puzzle: a cell responds to cholesterol that reaches its interior, not low-density lipoprotein (LDL) merely surrounding it.** Their radioactive-iodine measurements supplied the evidence: normal skin cells took up LDL, while FH cells barely did.

(Acetyl-CoA, the two-carbon unit that can burn for energy in the mitochondrion, also becomes storage fat and membrane phospholipids. This lesson follows cholesterol; the other two fates are in Going deeper. Building the fatty acids themselves has its own lesson, [fatty acid synthesis](https://stemhop.com/lessons/fatty-acid-synthesis/).)

> **The one idea to carry through this lesson.** The film above shows how ER cholesterol controls both synthesis and LDL uptake in liver cells through SREBP cleavage-activating protein (SCAP), SREBP-2 and Insig. A statin, cholesterol-absorption blocker or bile-acid resin lowers liver-cell ER cholesterol and therefore tends to raise LDL receptors.

Liver cells carry most of the body’s LDL receptors. This rule covers the sterol arm and has four limits, listed after the drugs.

## The spine: condense, assemble, cyclize

All 27 of cholesterol’s carbons come from acetyl-CoA, across roughly thirty enzymatic steps, as Konrad Bloch and his colleagues proved with labeled acetate (Stories & asides has the shark-tank detour).

**Condense** (in the cytosol, ending on the ER membrane). Two acetyl-CoA make acetoacetyl-CoA, and a third gives 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), a six-carbon molecule. Then HMG-CoA reductase uses two NADPH to make **mevalonate**. The reductase sits in the ER membrane, its working end facing the cytosol. It runs the main rate-limiting, irreversible step, and it is the most important enzyme in this lesson.

**Assemble.** Three ATP phosphorylate mevalonate, and it loses one CO₂ to become **isopentenyl pyrophosphate (IPP)**, the universal five-carbon unit. Molecules built from these C5 units are called isoprenoids. Each C5 unit has a pyrophosphate “head” and a branched “tail”. IPP and its isomer DMAPP join head to tail, releasing pyrophosphate each time: C5 plus C5 gives geranyl-PP (C10), and one more C5 gives farnesyl-PP (C15). Squalene synthase then joins two farnesyl-PP at their heads, the pyrophosphate ends, releasing both pyrophosphates and using one NADPH. The product is **squalene** (C30), and because the heads were joined, it has a tail at each end. (Textbooks name this one reaction both ways, “head to head” and “tail to tail”; it is the same coupling.) Hydrolysis of the released pyrophosphate pulls each coupling forward.

**Cyclize.** Squalene monooxygenase uses O₂ and NADPH to put an epoxide on one end of squalene, making 2,3-oxidosqualene. Oxidosqualene cyclase then builds all four fused rings and sets the stereochemistry in a single turnover, one of the most elegant enzyme steps in biochemistry. The product is **lanosterol**. Roughly nineteen more steps, many using O₂ and NADPH, trim it to cholesterol. (The film splits the same road slightly differently: its first stage runs all the way to the isoprene unit.)

**Predict.** Eighteen acetyl-CoA go into one cholesterol, bringing 36 carbons. Cholesterol has 27. Where do the other nine go?

> **Check your prediction.** Six leave as CO₂, one from each mevalonate as it becomes IPP, so six IPP carry 30 carbons. Squalene and lanosterol keep all 30, and the trimming removes three methyl groups, leaving 27. The ledger:
>
> | Stage | Carbons | Spent on the way |
> | --- | --- | --- |
> | 18 acetyl-CoA | 18 × 2 = 36 | — |
> | 6 mevalonate | 6 × 6 = 36 | 6 × 2 = 12 NADPH at the reductase |
> | 6 IPP | 6 × 5 = 30 (6 CO₂ lost) | 6 × 3 = 18 ATP |
> | squalene, 2,3-oxidosqualene, lanosterol | 30 | 1 NADPH at squalene synthase, 1 at squalene monooxygenase |
> | cholesterol | 27 (3 methyls trimmed) | many more NADPH and O₂ in the trimming |

So making one cholesterol costs 18 acetyl-CoA, 18 ATP and 14 NADPH (12 + 1 + 1) just to reach the epoxide, with more to come in the trimming.

Walk the spine below. Its meter counts each step once; the ledger multiplies by six where a step runs six times.

*Interactive on the lesson page:* Cholesterol synthesis · acetyl-CoA to sterol tap a step to reveal it Running total 0 ATP0 NADPH0 CO₂ regulated step − us

## Where the throttle sits

Mevalonate is not only the road to cholesterol. Its C5 units also feed CoQ10, dolichol, the side chain of one form of vitamin K, and the prenyl anchors (farnesyl-PP, geranylgeranyl-PP) that tether signaling proteins such as Ras to membranes. So the pathway is a trunk that branches: everything up to farnesyl-PP is shared, and carbon turns into the sterol branch only at squalene synthase.

The cell puts its main brake at the reductase, so it stops carbon before any ATP is spent on the phosphorylation steps. A step is called committed when carbon that passes it has left the general pool for one pathway: the reductase commits carbon to the mevalonate trunk (which still branches), and squalene synthase commits it to sterols alone. The reductase is the main throttle, not the only one. Squalene monooxygenase is a second regulated point, and the gauge raises nearly every enzyme of the pathway.

**Predict.** One drug blocks 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (a statin). A research compound blocks squalene synthase instead. Which one also lowers CoQ10?

> **Check your prediction.** The statin. CoQ10 branches off above squalene synthase, so blocking squalene synthase spares it. A statin acts at the top of the trunk and cuts the whole isoprenoid supply, CoQ10 and the prenyl anchors included. That branching is why statins have effects beyond cholesterol.

*Figure (AI-generated illustration).* Mevalonate feeds a shared trunk. HMG-CoA reductase, the main throttle, sits at the top, so a statin cuts the whole isoprenoid supply, CoQ10 and the prenyl anchors included; squalene synthase commits carbon to sterols only, so blocking it spares the side branches. Image: the mevalonate pathway drawn as a pipe. Acetyl-CoA flows to HMG-CoA, through a gold valve labelled HMG-CoA reductase, to mevalonate, IPP and farnesyl-PP, where side branches lead to CoQ10, dolichol, prenyl anchors and vitamin K; the main line passes a second valve, squalene synthase, to squalene, lanosterol and cholesterol. An inset shows that a statin greys out every branch, while a squalene synthase inhibitor greys out only the sterol branch.

## How LDL gets in

The second supply line starts in the blood, so follow the particle the liver’s receptors pull back in. Cholesterol does not dissolve in blood, so it rides in lipoproteins: a shell of phospholipid, free cholesterol and apolipoprotein around a core of triacylglycerol and cholesteryl ester. ApoB-100 is the address label the LDL receptor reads. The liver secretes VLDL (very-low-density lipoprotein); lipoprotein lipase strips its triglyceride to make IDL (intermediate-density lipoprotein); hepatic lipase finishes the job to make LDL. LDL is made in the blood, not secreted as such.

Cells take LDL up by receptor-mediated endocytosis. ApoB-100 binds the receptor, and the receptors cluster into a clathrin-coated pit that pinches off as a vesicle. In the acidic endosome the LDL lets go of its receptor. The receptor recycles to the cell surface, while the LDL goes on to the lysosome, which breaks it down and releases free cholesterol. HDL runs the traffic in reverse, pulling cholesterol back to the liver.

*Figure (AI-generated illustration).* The LDL receptor reads ApoB-100, the pit pinches off, the receptor recycles and the LDL goes on to the lysosome; PCSK9 sends the receptor to the lysosome instead, so fewer receptors return to the surface. Image: a left-to-right schematic of LDL being taken into a cell, with an LDL bead bound to receptors at a clathrin-coated pit, an endosome where the receptors recycle to the surface, and a lysosome where the LDL releases free cholesterol, plus an inset where PCSK9 sends a receptor to the lysosome.

If the receptor is missing or broken, LDL stays in the blood. That is familial hypercholesterolemia, an inherited disorder usually caused by an LDL-receptor mutation, found in roughly one person in 250, and the disease that cracked the whole system open. Brown and Goldstein proved FH is a disorder of uptake, not synthesis. Even a receptor that binds LDL fails if it never gathers into a pit (Stories & asides, “Binding is not enough”).

## One gauge, two supply lines

Making cholesterol is expensive and importing it is cheap; the reductase sits in the ER membrane. The film above shows how cholesterol in that membrane controls both supply lines. Here are the molecular parts. **SREBP-2** (sterol regulatory element-binding protein 2) is a transcription factor made in an inactive form stuck in the ER membrane; it is the passenger. **SREBP cleavage-activating protein (SCAP)** is its escort, and SCAP’s sterol-sensing domain is what actually reads cholesterol. **Insig** is an ER membrane protein that grabs SCAP once SCAP has bound cholesterol.

|  | ER cholesterol low | ER cholesterol high |
| --- | --- | --- |
| SCAP | has no cholesterol bound, so Insig leaves it alone | binds cholesterol, changes shape, and is grabbed by Insig |
| The SCAP-SREBP-2 pair | is packed into COPII vesicles bound for the Golgi | is held in the ER |
| SREBP-2 | is cut twice in the Golgi, first by the protease S1P and then by S2P; the freed piece enters the nucleus and binds the sterol regulatory element | never reaches the proteases and stays inactive |
| Genes switched on | the reductase and the other synthesis enzymes, **and the LDL receptor** | none of them, so their expression falls |

The bottom row is the point: one switch turns on **both** supply lines.

*Figure (AI-generated illustration).* One gauge sets both supply lines. When ER cholesterol is low, SCAP escorts SREBP-2 to the Golgi, where it is cut and freed to turn on the reductase and the LDL-receptor genes together; when it is high, cholesterol binds SCAP, Insig grips SCAP, and both lines are turned down. Insig and cholesterol act on SCAP, not on SREBP-2. Image: one liver cell drawn twice. On the left, with ER cholesterol low, SCAP carries SREBP-2 from the ER to the Golgi, a cut piece of SREBP-2 enters the nucleus, and the cell makes many HMG-CoA reductase enzymes on the ER and many LDL receptors at the surface. On the right, with ER cholesterol high, cholesterol sits on SCAP, Insig grips SCAP, the pair stays in the ER, and the cell has few reductase enzymes and few LDL receptors.

The film above keeps the wiring explicit: cholesterol binds SCAP, and Insig binds SCAP; SREBP is the passenger. Oxysterols such as 25-hydroxycholesterol bind Insig instead of SCAP; either way SCAP is held in the ER.

The gauge works over hours, because it changes how much protein is made. The reductase also has faster controls, each reading something specific.

| Control on the reductase | What it reads | What it does | How fast |
| --- | --- | --- | --- |
| Transcription (SREBP-2) | ER cholesterol | changes how much reductase is made | hours |
| Degradation | sterols, chiefly lanosterol-type intermediates and oxysterols, helped by nonsterol isoprenoids | when they are high, Insig sends the reductase for destruction in the ER | tens of minutes to hours |
| Translation | nonsterol products of mevalonate | slows reading of the reductase mRNA | minutes to hours |
| Phosphorylation (AMPK) | the cell’s energy charge, not sterols | switches the enzyme off when ATP is low | minutes |

Three of the four read the pathway’s own products; only AMPK reads fuel, a famine brake on an expensive molecule. These layers overlap: sterols act through Insig at two of them. Of the four, only the transcription control, the gauge itself, also sets the low-density lipoprotein (LDL) receptor.

**Predict.** A statin blocks the reductase, so the liver makes less cholesterol. What happens to the number of LDL receptors on a liver cell, and to LDL in the blood?

> **Check your prediction.** Receptors go up and blood LDL goes down. With less synthesis, ER cholesterol falls, the gauge reads low, and freed SREBP-2 turns on the LDL-receptor gene. The statin closes one supply line and the gauge opens the other, so a drug that blocks synthesis ends up working largely by boosting uptake. Statins lower blood LDL on average by 30 to 50 percent.

Statins are nanomolar competitive inhibitors shaped like the reaction intermediate. The low reading also turns the reductase gene up, so a treated cell makes extra reductase for the drug to block. That compensation is part of the “rat paradox” Akira Endo ran into (Stories & asides).

**Predict.** A child has no working LDL receptors. Her blood LDL is several times normal. Brown and Goldstein grew her skin cells in a dish with LDL in the medium. Do those cells make more cholesterol than normal cells, or less?

> **Check your prediction.** More. No LDL gets in, so the cell’s gauge reads low however much LDL is in the medium, and SREBP-2 keeps synthesis running. That is what Brown and Goldstein saw in the skin cells at the top of this lesson: the cells’ chemistry worked, but nothing told them to stop. (In the whole body her liver still gets cholesterol by other routes, so her blood LDL is high mainly because LDL is cleared slowly, not because her liver makes much more.)

Try both cases in the thermostat below: set how much cholesterol reaches the cell, toggle the statin, and follow the chain from ER cholesterol to blood LDL.

*Interactive on the lesson page:* The cholesterol thermostat — SCAP, SREBP-2 and the statin

## Same gauge, more drugs

SREBP-2 also turns on the gene for **PCSK9**, a secreted protein that binds the low-density lipoprotein (LDL) receptor and sends it to the lysosome to be destroyed, so fewer receptors return to the surface. A statin therefore raises PCSK9 along with the receptors, and gives back part of its gain.

**Predict.** A patient already on a statin adds an antibody that blocks PCSK9. Why does her LDL fall further?

> **Check your prediction.** With PCSK9 blocked, more of the receptors the statin ordered survive. PCSK9 antibodies lower LDL by about 55 percent, alone or on top of a statin; inclisiran instead silences PCSK9’s mRNA in the liver.

Two more drugs act from the gut side. Ezetimibe blocks cholesterol absorption, so less cholesterol reaches the liver from the gut. Bile-acid resins trap bile acids in the gut, so the liver converts more of its own cholesterol into new bile acids. Either way the liver cell’s ER cholesterol falls, and the gauge answers with more receptors.

**Where the rule stops.**

- **The energy brake is separate.** AMP-activated protein kinase (AMPK) (last row of the table) also switches off fatty-acid synthesis, and it acts mainly on the enzyme itself, not through the sterol gauge.
- **The gauge brakes itself** through PCSK9, as above.
- **It needs working receptors.** Without them, as in the familial hypercholesterolemia (FH) child, the gauge calls for receptors that cannot be added, so a statin loses most of its LDL-lowering step.
- **Fat synthesis follows a different lead.** A sister factor, SREBP-1c, also escorted by SREBP cleavage-activating protein (SCAP), drives fatty acid synthase and answers mainly to insulin.

## What cholesterol becomes

Most of a cell’s cholesterol stays in its membranes, and excess is stored as cholesteryl ester (the liver also exports it in lipoproteins). In particular tissues, cholesterol, or for vitamin D a late precursor, is also the scaffold for three kinds of product, each tailored by known enzymes:

- **Bile salts.** CYP7A1, the 7alpha-hydroxylase, commits cholesterol to bile salts.
- **Steroid hormones** (glucocorticoids, mineralocorticoids and sex steroids), tailored by tissue-specific enzymes such as the P450 aromatase, which makes estrogens, and 5alpha-reductase.
- **Vitamin D**, a secosteroid hormone made in skin from 7-dehydrocholesterol, a late precursor of cholesterol, then activated in liver and kidney.

Many drugs in this lesson, from statins to finasteride (a 5alpha-reductase inhibitor) to aromatase inhibitors, work by blocking one known enzyme in the pathway. In the chapter on integration of metabolism, these same switches answer to the fed and fasted state.

## Going deeper

### The other two fates of acetyl-CoA: the phosphatidate hub

Storage fat and membrane phospholipids share a backbone. GPAT adds a fatty acid to glycerol 3-phosphate at the sn-1 position, making lysophosphatidate; AGPAT adds the second at sn-2, making **phosphatidate**. The positions show up in downstream lipids: sn-1 tends to carry a saturated chain, sn-2 an unsaturated one. Mind the name. Phosphatidate is diacylglycerol-3-phosphate, not diacylglycerol; the phosphate is the whole point.

Phosphatidate is the fork, and it splits two ways:

- **Remove the phosphate.** PAP activity, carried by the lipin enzymes (Lipin 1 is the best studied of three), gives diacylglycerol. Diacylglycerol is acylated a third time into triacylglycerol, the storage form. But it also feeds membranes: the two most abundant membrane lipids, phosphatidylcholine and phosphatidylethanolamine, are made by handing diacylglycerol an activated head group from CDP-choline or CDP-ethanolamine.
- **Add CTP.** Phosphatidate becomes CDP-diacylglycerol, the activated donor for phosphatidylinositol, phosphatidylglycerol and cardiolipin (and, in bacteria and yeast, phosphatidylserine).

The CDP steps use the activated-intermediate logic you have seen with UDP-sugars: making the activated head group releases pyrophosphate, whose hydrolysis pulls the reaction forward.

### Lipin 1 localization in cultured fat cells

PAP is also controlled by where it sits. Less phosphorylated Lipin 1 binds the ER membrane, where its substrate lives, and makes diacylglycerol. More heavily phosphorylated Lipin 1 stays mostly in the cytosol, away from its substrate, and makes less. The effects depend on the lipin paralog, its phosphorylation and the cell type. In cultured fat cells, epinephrine and the fatty acid oleate dephosphorylate Lipin 1 and move it onto the membrane, while insulin, surprisingly, phosphorylates it and shifts more of it into the cytosol. Losing Lipin 1 causes lipodystrophy in mice and recurrent muscle breakdown (rhabdomyolysis) in children. Where an enzyme sits can matter as much as how much of it there is.

*Figure (AI-generated illustration).* Lipin 1 localization changes its access to substrate at the ER membrane: less phosphorylated Lipin 1 associates more with the membrane and makes more diacylglycerol; more heavily phosphorylated Lipin 1 is mostly cytosolic and makes less. The diacylglycerol supplies both storage fat and membrane phospholipids. Image: two side-by-side panels of Lipin 1 at the ER membrane. Left, less phosphorylated Lipin 1 sits on the membrane next to its substrate phosphatidate, with a thick gold arrow to more diacylglycerol. Right, more phosphorylated Lipin 1 with phosphate flags floats in the cytosol, with a thin dashed arrow to less diacylglycerol.

### Sphingolipids and Tay-Sachs disease

Sphingolipids run on a different backbone entirely. Palmitoyl-CoA condenses with serine, and after a few steps you reach **ceramide**, the sphingolipid hub. Add phosphocholine and you get sphingomyelin; add sugars and you get cerebrosides and then gangliosides. The clinical anchor is Tay-Sachs disease: loss of hexosaminidase A blocks breakdown of the ganglioside GM2, which builds up in the lysosomes of neurons, and the result is fatal neurodegeneration.

### More branches of the mevalonate trunk

The shared trunk above squalene synthase is why statins reach beyond cholesterol, and three details fill it in. The vitamin K made from mevalonate is MK-4, whose side chain is built on a ring taken from dietary vitamin K. Nitrogen-containing bisphosphonates, the main osteoporosis drugs of this class, inhibit farnesyl-PP synthase in osteoclasts, below mevalonate on the shared trunk. And while farnesyl-PP anchors Ras, geranylgeranyl-PP anchors Rho-family GTPases.

### The numbers behind HMG-CoA reductase control

The four controls in the reductase table come with sizes. In cultured cells, sterol and nonsterol feedback together can change the amount of enzyme more than 200-fold. AMP-activated protein kinase (AMPK) phosphorylates the enzyme at Ser872. Sterol-triggered degradation can cut the enzyme’s half-life more than tenfold.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/lipid-synthesis/
